玻璃体注射康柏西普治疗视网膜中央静脉阻塞继发黄斑水肿一年疗效观察

One-year efficacy of intravitreal Conbercept injection for macular edema secondary to central retinal vein occlusion

目的观察玻璃体注射康柏西普治疗视网膜中央静脉阻塞(CRVO)继发性黄斑水肿一年的疗效。设计回顾性系列病例。研究对象CRVO继发性黄斑水肿患者27例27眼。方法患者接受每月玻璃体注射康柏西普0.5 mg,连续3个月;其后每月随访按需注射至12个月(3+PRN)。治疗前及随访时检测患眼最佳矫正视力(BCVA)、BCVA提高三行者的百分比,相干光断层扫描(OCT)检测中心视网膜厚度(CRT),记录一年总注射次数及安全性。主要指标BCVA、CRT。结果治疗后第3及第12个月,患者平均BCVA较治疗前分别提高(12.7±7.6)及(14.8±9.6)个EDTRS字母;平均CRT分别减少(374.5±280.7)μm及(428.2±241.3)μm;BCVA提高3行患者的百分比分别为45.1%及52.9%。一年平均总注射次数为(7.6±1.5)针。未发现局部及全身严重不良反应。结论采用3+PRN策略进行玻璃体注射康柏西普治疗CRVO继发性黄斑水肿,随访一年证实安全有效。

Objective To evaluate the 1-year follow-up efficacy of intravitreal injection of Conbercept for treatment of macular edema secondary to central retinal vein occlusion(CRVO).Design Retrospective case series.Participant Twenty-seven eyes in 27 patients with macular edema associated with CRVO were retrospectively reviewed.Methods The CRVO eyes received monthly intravitreal injection of Conbercept(0.5 mg)for 3 months.From then on,the patients were followed up monthly and received PRN injection up to 12 months.Main Outcome Measures Best-corrected visual acuity(BCVA),central retinal thickness(CRT),proportion of patients gaining≥15 EDTRS letters,the number of total injections in one-year and safty.Results The mean BCVA gain from baseline was 12.7±7.6 letters at month 3 and 14.8±9.6 letters at month 12.The mean CRT reduction from baseline was(374.5±280.7)μm at month 3 and(428.2±241.3)μm at month 12.The proportion of patients who gained≥15 letters in BCVA was 45.1%at month 3 and 52.9%at month 12.The mean number of injections was 7.6±1.5.No severe local and systemic complications occurred following injection.Conclusion Intravitreal injection of Conbercept by 3+PRN regime was safe and efficacious for treatment of patients with macular edema secondary to CRVO through one-year follow-up.